Aratana Therapeutics, Inc. (NASDAQ:PETX) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Tuesday.

A number of other research analysts have also recently weighed in on the stock. Jefferies Group LLC restated a “buy” rating and set a $8.00 target price on shares of Aratana Therapeutics in a research note on Friday, May 5th. ValuEngine cut shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 31st. Stifel Nicolaus lowered their target price on shares of Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th. Finally, Zacks Investment Research cut shares of Aratana Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $10.00.

Shares of Aratana Therapeutics (NASDAQ PETX) traded down 1.518% during midday trading on Tuesday, hitting $6.165. The company had a trading volume of 231,695 shares. The stock has a 50 day moving average price of $7.07 and a 200 day moving average price of $6.46. Aratana Therapeutics has a 1-year low of $4.97 and a 1-year high of $10.73. The firm’s market capitalization is $234.00 million.

Aratana Therapeutics (NASDAQ:PETX) last released its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03. Aratana Therapeutics had a negative net margin of 642.93% and a negative return on equity of 52.00%. The company had revenue of $5.16 million for the quarter, compared to analysts’ expectations of $4.50 million. During the same quarter in the previous year, the company earned $0.61 EPS. Aratana Therapeutics’s revenue for the quarter was down 86.4% on a year-over-year basis. On average, equities analysts anticipate that Aratana Therapeutics will post ($1.04) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Aratana Therapeutics, Inc. (NASDAQ:PETX) Cut to Strong Sell at BidaskClub” was published by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/08/aratana-therapeutics-inc-nasdaqpetx-cut-to-strong-sell-at-bidaskclub.html.

A number of hedge funds have recently made changes to their positions in PETX. AQR Capital Management LLC boosted its stake in shares of Aratana Therapeutics by 81.9% in the fourth quarter. AQR Capital Management LLC now owns 65,079 shares of the biopharmaceutical company’s stock valued at $467,000 after buying an additional 29,306 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Aratana Therapeutics by 281.4% in the first quarter. Wells Fargo & Company MN now owns 276,152 shares of the biopharmaceutical company’s stock valued at $1,464,000 after buying an additional 203,738 shares during the last quarter. General American Investors Co. Inc. boosted its stake in shares of Aratana Therapeutics by 8.0% in the first quarter. General American Investors Co. Inc. now owns 524,459 shares of the biopharmaceutical company’s stock valued at $2,780,000 after buying an additional 38,991 shares during the last quarter. Tocqueville Asset Management L.P. boosted its stake in shares of Aratana Therapeutics by 56.3% in the first quarter. Tocqueville Asset Management L.P. now owns 250,000 shares of the biopharmaceutical company’s stock valued at $1,325,000 after buying an additional 90,000 shares during the last quarter. Finally, Geneva Advisors LLC boosted its stake in shares of Aratana Therapeutics by 4.1% in the first quarter. Geneva Advisors LLC now owns 77,288 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 3,044 shares during the last quarter. Institutional investors and hedge funds own 67.85% of the company’s stock.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.